AstraZeneca: sells rights to hypertension drug Atacand
(CercleFinance.com) - AstraZeneca has agreed to sell the commercial rights to heart failure and hypertension drug Atacand in Europe to Cheplapharm for a total of 210 million dollars, the drugmaker said.
Under the terms of the deal, AstraZeneca will continue to manufacture and supply Atacand under a supply agreement and will continue to commercialise the drug in all markets where it still holds the rights.
The move comes as AstraZeneca is seeking to streamline its portfolio of mature medicines to reinvest in more promising therapy areas and bring new medicines to the market.
The agreement is expected to complete in the third quarter, AstraZeneca said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Under the terms of the deal, AstraZeneca will continue to manufacture and supply Atacand under a supply agreement and will continue to commercialise the drug in all markets where it still holds the rights.
The move comes as AstraZeneca is seeking to streamline its portfolio of mature medicines to reinvest in more promising therapy areas and bring new medicines to the market.
The agreement is expected to complete in the third quarter, AstraZeneca said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.